[go: up one dir, main page]

ES8404346A1 - Un procedimiento para la preparacion de diarilpirazinas o triazinas. - Google Patents

Un procedimiento para la preparacion de diarilpirazinas o triazinas.

Info

Publication number
ES8404346A1
ES8404346A1 ES520340A ES520340A ES8404346A1 ES 8404346 A1 ES8404346 A1 ES 8404346A1 ES 520340 A ES520340 A ES 520340A ES 520340 A ES520340 A ES 520340A ES 8404346 A1 ES8404346 A1 ES 8404346A1
Authority
ES
Spain
Prior art keywords
formula
procedure
triazinas
diarilpirazinas
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES520340A
Other languages
English (en)
Other versions
ES520340A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES8404346A1 publication Critical patent/ES8404346A1/es
Publication of ES520340A0 publication Critical patent/ES520340A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE DIARILPIRAZINAS O TRIAZINAS Y DE SUS SALES FISIOLOGICAMENTE COMPATIBLES, DE FORMULA (I), EN LA QUE R1 Y R2 SON ALQUILO C1-3 O CLORO; X ES NITROGENO O CH; Q ES OXIGENO O -(CH2)N- DONDE N VALE 0-2 Y W PUEDE SER VARIOS RADICALES.CONSISTE EN LA REACCION DE SUSTITUCION NUCLEOFILICA DE UN COMPUESTO DE FORMULA (II) CON UNA AMINA DE FORMULA (III), EN LAS QUE R3 ES UN GRUPO CAPAZ DE SER SUSTITUIDO Y LOS DEMAS SIMBOLOS TIENEN LOS MISMOS SIGNIFICADOS QUE EN LA FORMULA (I). LA REACCION SE LLEVA A CABO EN UN DISOLVENTE INERTE O EN SUAUSENCIA, EN PRESENCIA DE UNA BASE A UNA TEMPERATURA ENTRE 80JC Y 150JC.ESTOS COMPUESTOS TIENEN APLICACIONES FARMACOLOGICAS COMO ACTIVANTES DE LA UNION DEL ACIDO GAMMA-AMINOBUTIRICO Y LA BENZODIAZEPINA EN EL SISTEMA NERVIOSO CENTRAL.
ES520340A 1982-03-05 1983-03-04 Un procedimiento para la preparacion de diarilpirazinas o triazinas. Granted ES520340A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/354,982 US4513135A (en) 1982-03-05 1982-03-05 Diaryl-pyrazine derivatives affecting GABA binding

Publications (2)

Publication Number Publication Date
ES8404346A1 true ES8404346A1 (es) 1984-04-16
ES520340A0 ES520340A0 (es) 1984-04-16

Family

ID=23395746

Family Applications (2)

Application Number Title Priority Date Filing Date
ES520340A Granted ES520340A0 (es) 1982-03-05 1983-03-04 Un procedimiento para la preparacion de diarilpirazinas o triazinas.
ES526297A Expired ES8504173A1 (es) 1982-03-05 1983-10-06 Un procedimiento para la preparacion de diarilpirazinas o triazinas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES526297A Expired ES8504173A1 (es) 1982-03-05 1983-10-06 Un procedimiento para la preparacion de diarilpirazinas o triazinas

Country Status (22)

Country Link
US (2) US4513135A (es)
EP (1) EP0088593B1 (es)
JP (1) JPS58162582A (es)
KR (1) KR860000847B1 (es)
AT (1) ATE27457T1 (es)
AU (1) AU547581B2 (es)
CA (1) CA1195327A (es)
DD (1) DD207716A5 (es)
DE (1) DE3371786D1 (es)
DK (1) DK97283A (es)
ES (2) ES520340A0 (es)
FI (1) FI830708A7 (es)
GB (1) GB2116179B (es)
GR (1) GR78459B (es)
HU (1) HU191368B (es)
IL (1) IL68002A (es)
NZ (1) NZ203428A (es)
PH (1) PH22535A (es)
PL (1) PL240871A1 (es)
PT (1) PT76312B (es)
RO (1) RO86320B (es)
ZA (1) ZA831387B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) * 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
CA2596359A1 (en) * 2005-02-01 2006-08-10 Lake Erie Products Anti-cross threading fastener
CA2606288A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja) * 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2531492B1 (en) 2010-02-05 2016-04-13 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
AR088256A1 (es) * 2011-10-08 2014-05-21 Novartis Ag Derivados de carbamato / urea como antagonistas del receptor h3
PH12019500056B1 (en) * 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US11339135B2 (en) 2016-11-30 2022-05-24 Mitsubishi Tanabe Pharma Corporation Method for producing triazine compound
AU2018210770B2 (en) 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
MX2020011565A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤によりがんを処置する方法
CN117304174A (zh) * 2022-06-20 2023-12-29 四川轻化工大学 一种5,6-二苯基吡嗪-2-氮杂环类化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172889A (en) * 1965-03-09 Process for the separation of z-methyl-
US3294638A (en) * 1961-06-05 1966-12-27 Warner Lambert Pharmaceutical Method and compositions employing 2-alkyl-3-piperidinopyrazines
CH480795A (de) * 1967-03-01 1969-11-15 Sandoz Ag Mittel zur Beeinflussung des Pflanzenwachstums
US4013654A (en) * 1974-01-31 1977-03-22 Eli Lilly And Company 5,6-diaryl-1,2,4-triazines
US3989831A (en) * 1974-01-31 1976-11-02 Eli Lilly And Company Topically-active anti-inflammatory 3-chloro-5,6-diaryl-1,2,4-triazines
US3948894A (en) * 1974-01-31 1976-04-06 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US3979516A (en) * 1974-01-31 1976-09-07 Eli Lilly And Company Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines
US4081542A (en) * 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
GB1493998A (en) * 1975-06-03 1977-12-07 Beecham Group Ltd Propanolamine derivatives
US4008232A (en) * 1975-06-23 1977-02-15 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4082844A (en) * 1976-02-09 1978-04-04 Merck & Co., Inc. 6-chloro-2-(1-piperazinyl)pyrazine
US4018923A (en) * 1976-03-10 1977-04-19 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
US4190725A (en) * 1976-03-10 1980-02-26 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines
US4021553A (en) * 1976-03-10 1977-05-03 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
DE2810052A1 (de) * 1977-03-09 1978-09-14 Fabre Sa Pierre Aminoaryl-1,2,4-triazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
CH633541A5 (en) * 1977-05-17 1982-12-15 Diamond Shamrock Corp Pharmacologically active substituted 1,2,4-triazines and medicaments containing these triazines
US4251527A (en) * 1977-05-17 1981-02-17 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
US4157392A (en) * 1977-05-17 1979-06-05 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines

Also Published As

Publication number Publication date
RO86320B (ro) 1985-03-31
DE3371786D1 (en) 1987-07-02
GB2116179A (en) 1983-09-21
GB8305846D0 (en) 1983-04-07
GB2116179B (en) 1985-09-11
US4585861A (en) 1986-04-29
PL240871A1 (en) 1984-06-18
GR78459B (es) 1984-09-27
FI830708L (fi) 1983-09-06
FI830708A7 (fi) 1983-09-06
IL68002A0 (en) 1983-06-15
KR840004101A (ko) 1984-10-06
JPS58162582A (ja) 1983-09-27
PT76312B (en) 1986-02-04
DK97283D0 (da) 1983-02-28
HU191368B (en) 1987-02-27
US4513135A (en) 1985-04-23
EP0088593B1 (en) 1987-05-27
ES526297A0 (es) 1985-04-16
FI830708A0 (fi) 1983-03-02
DD207716A5 (de) 1984-03-14
KR860000847B1 (ko) 1986-07-09
NZ203428A (en) 1986-09-10
PT76312A (en) 1983-04-01
EP0088593A3 (en) 1984-05-23
AU547581B2 (en) 1985-10-24
IL68002A (en) 1986-09-30
RO86320A (ro) 1985-03-15
ES520340A0 (es) 1984-04-16
EP0088593A2 (en) 1983-09-14
CA1195327A (en) 1985-10-15
ES8504173A1 (es) 1985-04-16
ATE27457T1 (de) 1987-06-15
DK97283A (da) 1983-09-06
ZA831387B (en) 1984-10-31
PH22535A (en) 1988-10-17
AU1202983A (en) 1983-09-08

Similar Documents

Publication Publication Date Title
ES8404346A1 (es) Un procedimiento para la preparacion de diarilpirazinas o triazinas.
ES8603879A1 (es) Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas
ES8303382A1 (es) Un procedimiento para la preparacion de derivados del 1,2,5-tiadiazol.
ES8301966A1 (es) Procedimiento para preparar derivados de pirimidona
ES8104993A1 (es) Un procedimiento para preparar compuestos aromaticos susti- tuidos
ES8605791A1 (es) Un procedimiento para la preparacion de derivados de imida- zodiacepina
ES8400415A1 (es) "un procedimiento para la preparacion de derivados de 2,4-diaminoquinazolina".
ES8402306A1 (es) Un procedimiento para la preparacion de nuevos derivados de oxabicicloalcano.
ES8301210A1 (es) Un procedimiento para la preparacion de un derivado del indol.
ES8500727A1 (es) Procedimiento para la obtencion de derivados de feniletilamina
ES8300677A1 (es) Un procedimiento para preparar compuestos de aminoetanol
ES8505997A1 (es) Un procedimiento para la preparacion de dihidropiridinas
ES8401025A1 (es) Procedimiento para la obtencion de acidos 1-carboxi-(azaalcanoil o azaaralcanoil)-indolin-2-carboxilicos.
ES8301980A1 (es) Procedimiento para la preparacion de 8-arilalcohil-3-fenil-3-nortropanoles .
ES8307824A1 (es) Un procedimiento para preparar nuevos compuestos de cefem.
ES8306749A1 (es) Un procedimiento para la preparacion de 2-guanidino-4-heteroariltiazoles.
ES8703437A1 (es) Procedimiento para la preparacion de 4h-3,1-benzoxazin-4-- onas y compuestos relacionados
ES8305755A1 (es) Procedimiento para preparar derivados de pirimidona.
ES8704932A1 (es) Procedimiento para preparar un derivado de acido quinoloncarboxilico
ES8301883A1 (es) Procedimiento para la preparacion de derivados de ciclohexe-no
ES8506707A1 (es) Un derivado de acido tiazolilacetico
ES8202001A1 (es) Procedimiento de producir dihidropiridinas n-morfolinoalqui-licas
ES8401077A1 (es) Procedimiento para la obtencion de esteres del acido 7 2(2-amino-4-tiazolil)-2-(sin)-metoxiiminoacetamido)-3-cefem-4-carboxilico.
ES8606880A1 (es) Un procedimiento para la preparacion de nuevos peptidos.
ES8304975A1 (es) "procedimiento para la preparacion de derivados triptaminicos sustituidos de tieniloxipropanolaminas, racemicos y opticamente activos".